by Madaline Spencer and Joe Haddad | Sep 3, 2026
The US Food and Drug Administration (FDA) has approved Mimrylo (rusfertide) for the treatment of adults with polycythemia vera (PV). PV is a condition characterized by an increased production of red blood cells. Affected people may also have excess white blood cells...
by Madaline Spencer | Sep 3, 2026
The US Food and Drug Administration (FDA) has approved Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET). ET is a condition characterized by an overproduction of platelets. Abnormal blood clotting is common in these...
by Madaline Spencer | Aug 31, 2026
The US Food and Drug Administration (FDA) has approved Lisraya (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). DM is a rare autoimmune condition that targets small blood vessels in the skin and muscle. Symptoms can include a red skin rash...
by Madaline Spencer | Aug 31, 2026
Eric Scheeff, PhD, Chief Scientific Officer at iDefine, discusses the treatment development of RNA amplifiers in patients with Kleefstra syndrome. Kleefstra syndrome is a rare disorder characterized by developmental delay and intellectual disability,...
by Madaline Spencer | Aug 28, 2026
Henry Kaminski, MD, Department of Neurology, and Linda Kusner, PhD, Department of Pharmacology & Physiology at George Washington University, discuss predicting response outcomes with proteomic and machine learning analyses in treating patients with myasthenia...
